Blue Earth Diagnostics Highlights Presentations on Axumin (Fluciclovine F 18) and Investigational 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer

The oral presentation includes additional results from Blue Earth's Phase 3 SPOTLIGHT study evaluating the impact of clinical factors on the detection rate of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy

Related Keywords

Medstar Georgetown University Hospital ,District Of Columbia ,United States ,Long Island ,Washington ,San Antonio ,Texas ,Edward Obedian ,Michael Carrasquilla ,Graham Campbell ,Benjamin Lowentritt ,Company Phase ,Winship Cancer Institute Of Emory University ,American Society For Radiation Oncology ,Department Of Radiation Medicine ,Department Of Radiation Oncology ,Henryb Gonzalez Convention Center ,Chesapeake Urology Associates ,University Of Wisconsin Hospital ,Blue Earth Diagnostics ,American Society ,Radiation Oncology ,Prostate Specific Membrane Antigen ,Industry Expert Theater ,Clinical Factors ,Recurrent Prostate Cancer ,Prostate Cancer ,Convention Center ,F Fluciclovine Positron Emission Tomography ,Biochemically Recurrent ,Wisconsin Hospital ,Genitourinary Cancer ,Patient Safety ,Exhibit Hall ,Potentially Salvageable Recurrences Following ,Clinically Localized Prostate Cancer Assessed ,Preferential Amino Acid Uptake ,Radiation Medicine ,Interim Volumetric ,Patient Reported Toxicity Analyses ,Ramesh Dhere ,Winship Cancer Institute ,Emory University ,Earth Diagnostics ,Exhibit Booth ,Radiation Oncologist ,Francis Hospital ,Meeting Level ,Important Safety Information About Axumin ,